Compound Summary
cilostazol
Compound Information
cilostazol
Compound Name: | cilostazol |
Compound CID: | 2754 |
Synonyms: | cilostazol 73963-72-1 Pletal Cilostazole Pletaal More... |
Iupac Name: | 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one |
InChI: | InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26) |
InChIKey: | RRGUKTPIGVIEKM-UHFFFAOYSA-N |
Canonical Smiles: | C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4 |
Isomeric Smiles: | C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4 |
Molecular Weight: | 369.5 |
Molecular Formula: | C20H27N5O2 |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
cilostazol
Molecular Weight: | 369.5 |
Molecular Formula: | C20H27N5O2 |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 7 |
Heavy Atom Count: | 27 |
Complexity: | 485 |
Synonyms
cilostazol
| cilostazol | cilostazol |
|---|---|
cilostazol |
73963-72-1 |
Pletal |
Cilostazole |
Pletaal |
OPC-13013 |
Cilostazolum |
Cilostazolum INN-Latin |
OPC 13013 |
OPC 21 |
OPC-21 |
6-4-(1-cyclohexyltetrazol-5-yl)butoxy-3,4-dihydro-1H-quinolin-2-one |
C20H27N5O2 |
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone |
UNII-N7Z035406B |
CHEBI:31401 |
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone |
6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one |
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril |
6-4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy-3,4-dihydroquinolin-2(1H)-one |
6-4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-yl)butoxy-1,2,3,4-tetrahydroquinolin-2-one |
MLS000028470 |
6-4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy-3,4-dihydro-2(1H)-quinolinone |
MFCD00866780 |
N7Z035406B |
NCGC00015207-07 |
SMR000058428 |
DSSTox_CID_25132 |
DSSTox_RID_80693 |
DSSTox_GSID_45132 |
CAS-73963-72-1 |
Pletal (TN) |
SR-01000003107 |
BRN 3632107 |
Cilostazol,(S) |
Cilostazol-d11 |
Cilostazol USAN:USP:INN:BAN:JAN |
Tocris-1692 |
Opera_ID_488 |
Spectrum2_001118 |
Spectrum3_001170 |
Spectrum4_000772 |
Spectrum5_001762 |
Lopac-C-0737 |
CHEMBL799 |
C 0737 |
Lopac0_000218 |
REGID_for_CID_2754 |
SCHEMBL16128 |
BSPBio_002759 |
KBioGR_001184 |
MLS000758281 |
MLS000759507 |
MLS001076067 |
MLS002153891 |
SPECTRUM1505230 |
SPBio_001256 |
Cilostazol (JP17/USP/INN) |
GTPL7148 |
DTXSID9045132 |
HSDB 8312 |
KBio3_002259 |
BCPP000279 |
HMS1922N15 |
HMS2093M14 |
HMS2096F16 |
HMS2234C06 |
HMS3260L17 |
HMS3268O09 |
HMS3412B18 |
HMS3654J13 |
HMS3676B18 |
HMS3713F16 |
Pharmakon1600-01505230 |
ACT02663 |
BCP03724 |
ZINC1552174 |
Tox21_110098 |
Tox21_500218 |
BDBM50225508 |
CCG-39646 |
NSC758936 |
s1294 |
AKOS015855512 |
Cilostazol, >=98% (HPLC), powder |
OPC 13013; OPC 21; Pletaal |
Tox21_110098_1 |
AC-4334 |
AM90304 |
BCP9000530 |
CS-1759 |
DB01166 |
KS-5154 |
LP00218 |
MCULE-8893820969 |
NSC 758936 |
NSC-758936 |
SDCCGSBI-0050206.P003 |
2(1H)-Quinolinone, 3,4-dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)- |
2(1H)-Quionlinone, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro- |
6-4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy-3,4-dihydro-2(1H)-quinolinone |
NCGC00015207-01 |
NCGC00015207-02 |
NCGC00015207-03 |
NCGC00015207-04 |
NCGC00015207-05 |
NCGC00015207-06 |
NCGC00015207-08 |
NCGC00015207-09 |
NCGC00015207-10 |
NCGC00015207-11 |
NCGC00015207-12 |
NCGC00015207-25 |
NCGC00022153-02 |
NCGC00022153-04 |
NCGC00022153-05 |
NCGC00022153-06 |
NCGC00022153-07 |
NCGC00260903-01 |
HY-17464 |
BCP0726000145 |
RETAL;PLETAL;OPC 21;PLETAAL;Cilostal |
SBI-0050206.P002 |
AB0012441 |
EU-0100218 |
FT-0602474 |
FT-0645036 |
FT-0665038 |
SW199053-2 |
D01896 |
F20538 |
J90029 |
AB00382988-14 |
AB00382988_15 |
AB00382988_16 |
963C721 |
A837982 |
Q258591 |
Q-200854 |
SR-01000003107-2 |
SR-01000003107-4 |
SR-01000003107-7 |
BRD-K67017579-001-04-2 |
BRD-K67017579-001-05-9 |
BRD-K67017579-001-07-5 |
BRD-K67017579-001-13-3 |
BRD-K67017579-001-17-4 |
SR-01000003107-10 |
Cilastatin sodium, Antibiotic for Culture Media Use Only |
Cilostazol, United States Pharmacopeia (USP) Reference Standard |
6-4-(1-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxy-3,4-dihydrocarbostyril |
6-4-(l-cyclohexyl-1,2,3,4-tetrazol-5-yl)butoxyl-3,4-dihydrocarbostyril |
Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material |
2(1H)-Quinolinone, 6-4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy-3,4-dihydro- |
6-(4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY)QUINOLINE-2,3(1H,4H)-DIONE |
6-4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy-3,4-dihydro-1H-quinolin-2-one |
89332-50-3 |
Experimental Data
cilostazol
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 9.000000000000000 | NS | N2 | 24134630 | Inactive |
Experimental Data Visualization
cilostazol
Statistics Data
cilostazol
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 9.000000000000000 | 1 | 1 |
Statistics Data Visualization
cilostazol
